Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1–3) and other prooncogenic and prooncogenic receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Tohyama, Osamu, Matsui, Junji, Kodama, Kotaro, Hata-Sugi, Naoko, Kimura, Takayuki, Okamoto, Kiyoshi, Minoshima, Yukinori, Iwata, Masao, Funahashi, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177084/
https://www.ncbi.nlm.nih.gov/pubmed/25295214
http://dx.doi.org/10.1155/2014/638747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177084/
https://www.ncbi.nlm.nih.gov/pubmed/25295214
http://dx.doi.org/10.1155/2014/638747

Ejemplares similares